BioSpace News Archive

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $90 million private placement, which is expected to close on or about December 15, 2020, subject to the satisfaction of customary closing conditions.

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of RINVOQ™ (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor, for the expanded use in two additional rheumatic indications: the treatment of adult patients with active psoriatic arthritis and adult patients with active ankylosing spondylitis

ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that ECT-001 Cell Therapy has been granted PRIority MEdicines (PRIME) designation by the European Medicines Agency (EMA) for use in urgent allogeneic haematopoietic stem cell transplants.

innovaTel Telepsychiatry, a leading provider of telebehavioral health services, has recently hired Jordana Bernard, MBA, FATA, as their Chief Compliance Officer. innovaTel looks forward to her expertise and guidance in support of innovaTel’s growth and primary mission to enhance timely access to care in an ever-changing, rapidly evolving regulatory environment. Jordana has over 30 years of experience driving organizational growth and advancement o

MISSISSAUGA, Ontario, Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase up to 950,000 of its common shares (“Shares”) over a 12-month period, representing approximately 7.42% of the Shares outstanding as of December 11, 2020. The NCIB will commence

Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company” ), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce a successful $15 million placement ( “Placement” ), led by a $10m investment from experienced healthcare investor BioScience Managers through the BioScience Managers Translation Fund I (BMTFI). BMTFI has a mandate to invest in Australian based innovative healthcare techn

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it had entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale, in a registered direct offering, of 20,312,500 shares of its common stock, par value $0.001 (the “Common Stock”), at a price of $3.20 per share, for aggregate gross proceeds to the Company of $65,000,000 before deducting fees to the placement agent a

PharmaBlock Sciences (Nanjing), Inc. (300725.SZ), a leading innovative chemistry product and service provider throughout the pharmaceutical R&D process, announced the signing of a strategic partnership agreement with Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases.

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that two U.S. patents which cover Phexxi® (lactic acid, citric acid and potassium bitartrate) and its labeled indication are now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

V2ACT Therapeutics™, LLC today announced that the Company has obtained permission from the U.S. Food and Drug Administration (FDA) on an Investigational New Drug (IND) application and may proceed with the clinical investigation of V2ACT in a Phase 1/2a trial for the treatment of newly diagnosed surgically-resectable pancreatic cancer patients.